AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting

Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.